Parkinson’s: Innovative method stops toxic protein buildup – Medical News Today

Instead of targeting the tricky protein behind Parkinsons, a new compound attacks the RNA that produces it.

Parkinsons disease is a neurodegenerative disorder characterized by tremor, slowness of movement, limb rigidity, and walking and balance issues.

In Parkinsons, a misfolded protein named -synuclein causes the degeneration and destruction of brain cells. The more -synuclein builds up, the more neurons die.

Now, scientists from Rutgers University in New Brunswick, NJ, and Scripps Research in Jupiter, Florida, have developed a way to decrease the amount of -synuclein the body produces.

New technology allowed scientists to identify a compound that shuts down the messenger RNA (mRNA) coding for the destructive protein, preventing the production of -synuclein and the progression of Parkinsons.

The researchers NIH-funded study appears in the Proceedings of the National Academy of Sciences.

According to the Parkinsons Foundation, over 10 million people worldwide are living with Parkinsons disease, with 1 million of those being in the United States.

Each year, about 60,000 U.S. adults receive a diagnosis of the disease.

The incidence of Parkinsons increases with age, although about 4% of people who receive a diagnosis are less than 50 years old. Men are 1.5 times more likely to develop Parkinsons than women.

Currently, there is no cure for Parkinsons disease, and it is truly a devastating disease, says neurology professor M. Maral Mouradian of Rutgers Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and a co-author of the study.

Numerous other approaches have attempted to address the production and buildup of -synuclein, but since the protein has no regular structure and continually changes shape, it has proven difficult to hit with medication.

Several other experimental drugs, says Mouradian, currently being tested for Parkinsons disease are antibodies that target a very late stage of -synuclein protein aggregates.

We want to prevent these protein clumps from forming in the first place before they do damage and lead to advancing disease.

The new research began when Mouradian reached out to chemistry professor Matthew D. Disney of Scripps to explore the potential for a new technology that Disney had invented for matching RNA structures with small-molecules or drug-like compounds.

The scientists had a hunch that they might find a match for the mRNA that coded for -synuclein and that the mRNA might offer a more stable, predictable target than -synuclein itself. The hunch paid off.

For the first time, we discovered a drug-like compound that has the potential to slow down the disease before it advances through an entirely new approach, says Mouradian.

They named their compound Synucleozid, and Mouradian describes it as highly promising.

While Synucleozid may be most effective in people with minimal symptoms and who are in the early stages of Parkinsons, Mouradian says, This new compound has the potential to [] change the course of life for people with this devastating disease.

Synucleozid may be of value beyond Parkinsons since -synuclein has implications in dementia with Lewy Bodies, another progressive condition that affects 1 million people in the U.S. alone.

The study also makes clear the promise of Disneys RNA/protein-matching technology. As Mouradian says, The reach of our study could go beyond people with Parkinsons disease to many other neurodegenerative diseases.

It is a classic example of how interdisciplinary research leads to significant change.

Follow this link:
Parkinson's: Innovative method stops toxic protein buildup - Medical News Today

Botox used as alternative solution for chronic migraines – The Denver Channel

COLORADO SPRINGS, Colo. -- Every 12 weeks, Shannon Stone goes to her neurologist to get Botox injected in and around her head. Not for cosmetic reasons, but for chronic migraines.

Ive been working with Stone for chronic migraines, said Dr. Andrea Manhart, a neurologist at UCHealth Colorado Springs. Shes gone from approximately daily migraines to three per month.

The whole process takes no more than five minutes and only needs to be done every few months.

It has really changed the world of neurology, Dr. Manhart said of Botox, a product normally associated with cosmetics and reducing wrinkles.

Stone gets Botox injected into 31 injection sites.

To be a candidate for Botox, you have to have more than 15 migraine headache days for a month and you have to fail three of the oral preventative therapies, Dr. Manhart said.

Stone fit that criteria.

Every migraine medication that they would give me was failing, or the side effects would be too bad to where I couldnt continue the medication any longer, Stone said.

To even begin to understand Stones pain, you have to know her story. She started getting migraines in 2002 and found Botox as a solution two years ago. Stone and her doctors believed the migraines stemmed from a car accident in 2002.

I fractured three vertebrae in my neck and the windshield went through the right side of my face, Stone explained. So, the healing of all of that just caused a lot of neurological and muscle and tissue damage.

It was a bad accident, we barely survived, said Robert McCall, Stones 17-year-old son.

Stone was nine months pregnant with McCall during the accident and as he grew up, he took on more of a role in the family to help when Stone was in pain.

I had to cook dinner a lot of the time and make sure my sisters got whatever they had to do for the night, homework and take a bath and stuff, McCall said.

There would be times where they would last for like three or four days at a time with minimal breaks, Stone said.

When Botox was presented to her as an option, her first fear was that her eyes would get droopy one of the side effects Dr. Manhart explained.

I never wanted to let any of my friends or people that I knew know that I was receiving Botox because I didnt want them to judge me or feel like I was doing it for a beauty type of thing, Stone said.

The FDA approved Botox as a treatment for chronic migraines back in 2010.

Botox is for a specific person, it is for a specific chronic migraine patient, Dr. Manhart said.

A study done by the American Society of Plastic Surgeons showed that three months after injection, patients treated with Botox had an average of 1.6 fewer migraine attacks per month.

How Botox works is relatively unknown but the theory is that it de-activates pain receptors in the brain to reduce neurotransmitters that send pain signals to the brain, Dr. Manhart said.

For Stone, its helped her spend more time with her kids.

You can really see an improvement in her and just her overall appearance, McCall said. She doesn't look down all the time, shes not always sleeping.

I can still move my eyebrows, I can still move my face, I just cant make an angry face, Stone said.

Follow this link:
Botox used as alternative solution for chronic migraines - The Denver Channel

Vagus nerve stimulation for treatment of headaches, other neurological conditions – Delray Newspaper

By: Dr. John Conde DC, DACNB Special to the Boca and Delray newspapers

The vagus nerve is a cranial nerve which is housed in the skull and is often referred to as the wandering nerve because it is the longest nerve in the human body. It travels from the brain stem to the outer ears and all the way down to the lower intestines. The vagus nerve is considered to be a part of the parasympathetic nervous system family, which is responsible for putting the body at rest, slowing the heart rate, enhancing digestion, sexual arousal, lacrimation (tearing), urination, normalizing blood vessel diameter, and defecation to name a few functions. These processes are the exact opposite of the sympathetic nervous system which is considered to be responsible for Fight or Flight dynamics.

Ideally, the predominance of activity should involve the parasympathetic nervous system with activation of the sympathetic nervous system only when appropriate, however this has not been the case for quite some time. Due to our lifestyle and the egregious demands our society places on us daily, this ratio of activation is completely thrown off. We develop a much greater sympathetic tone which is highly contributory to many neurological and psychological conditions. This is one of the reasons why there is such a high level of interest and research in vagus nerve stimulation and the recalibration of the ratio of parasympathetic versus sympathetic activity.

Invasive or surgical vagus nerve stimulation (VNS) involves the surgical implantation of a vagus nerve stimulator (pacemaker) for the treatment of seizures. This was FDA approved in 1997 for the treatment of seizures and then in 2005 for depression and 2015 for weight loss. However, due to the impracticality and danger associated with implantation of this stimulator researchers have been working tirelessly to ascertain a treatment modality that was non-surgical and non-invasive. They have finally succeeded. They have taken advantage of a small patch of tissue in the outer ear termed the cymba concha which is innervated by the auricular branch of the vagus nerve and found that stimulating this area with electrical current can have significant modulatory effects on the parasympathetic nervous system. Because the stimulation is occurring externally it is called transcutaneous vagus nerve stimulation (tVNS).

tVNS is garnering significant traction in several different medical specialties due to the wide-reaching effects this treatment can have. Headaches, specifically migraines are now being treated in many clinics with a combination of modalities that includes tVNS. The understanding is that in patients with chronic migraines there lies an irregularity in blood vessel diameter control such that vasodilation is prominent. Also an area in the brain stem that mediates head and face pain termed the trigeminal cervical complex (TCC) becomes irritated. Normalizing blood vessel diameter and activation of the TCC in the brainstem along with other targeted rehabilitation techniques can reduce migraine frequency and intensity. Other conditions being looked at for treatment include depression, tinnitus, epilepsy, pain, psychological conditions, dysautonomia, mood disorders, autism, and the global effects of aging. These are all mostly off-label but promising.

Dr. John Conde is a Board Certified Chiropractic Neurologist, one of only one thousand in the country. He holds diplomate status through the American Chiropractic Neurology Board. He provides specialized care for difficult cases of back neck pain, numbness-tingling, vertigo-dizziness balance disorders, fibromyalgia, migraines, AD/HD, autism, and dyslexia. His office is located at the Atlantic Grove in Delray Beach and can be reached at 561-330-6096, drconde@thecondecenter.com, http://www.thecondecenter.com

Original post:
Vagus nerve stimulation for treatment of headaches, other neurological conditions - Delray Newspaper

Sanofi investigated over epilepsy drug linked to birth defects – Physician’s Weekly

PARIS (Reuters) French drugmaker Sanofi said on Tuesday it was being investigated over Depakine, an epilepsy drug which caused birth malfunctions and slow neurological development when taken during pregnancy.

The Paris prosecutor had already launched a preliminary investigation into the authorization and marketing of Depakine in 2016, after Frances social affairs inspection agency IGAS criticized the slow response of health authorities and Sanofi to the risks related to the drug and its derivatives.

Sanofi said in a statement that the indictment, which may or may not lead to a trial, will allow it to defend itself and to prove it has always complied with its to duty to inform and been transparent.

Sanofi, which has repeatedly said it had no intention to compensate or take part in a state-backed compensation mechanism for Depakine, added it would continue to fully cooperate with judicial authorities, and was confident over the outcome.

Such legal cases can take years and do not necessarily result in significant amounts of compensation in France compared to other jurisdictions such as the United States.

In one of Frances biggest pharmaceutical scandals, privately-owned Servier has so far paid out 152.5 million euros ($169 million) to patients.

Sodium valproate, the active molecule in Depakine, has been on the market since 1967 to treat epilepsy and bipolar disorder. It features on the World Health Organizations (WHO) list of essential medicines.

Depakine, which lost its patent in 1998, is prescribed in more than 100 countries. It is also sold under the names Depakote and Epilim.

IGAS estimated that between 2006 and 2014, 425 to 450 babies suffered congenital birth defects or were stillborn following exposure to Depakine.

Marine Martin, president of victims association APESAC, said on Twitter she was extremely satisfied to see the criminal proceedings she launched in 2016 reach an important threshold.

Sanofi will have to deal with the tens of thousands of poisoned victims, out of which more than a hundred died.

The French firm become aware of the risk of fetus malformation in the 1980s and then, around 2003, of the drugs impact on the neurological development of the fetus, with a risk of autism or learning difficulties.

The U.S. Food and Drug Administration warned in 2013 that valproate should not be taken during pregnancy.

(Reporting by Benoit Van Overstraeten, Matthias Blamont; Editing by Christian Schmollinger and Alexander Smith)

Go here to read the rest:
Sanofi investigated over epilepsy drug linked to birth defects - Physician's Weekly

Review Highlights the Importance of Smoking Cessation in Patients With Multiple Sclerosis – Neurology Advisor

Cigarette smoking represents an important modifiable environmental risk factor for multiple sclerosis (MS), and a new review article suggests that smoking increases the risk for developing MS through increased inflammation and exposure to free radicals, cyanates, and carbon monoxide. This review was published in JAMA Neurology.

In this narrative review, Harvard researchers explored the relationship between cigarette smoking and MS risk and progression by examining reports in English-language studies. According to the literature, the prevalence of both MS and cigarette smoking jointly and substantially increased in the 20th century, particularly in women. Studies consistently report dose-response associations between smoking and MS, suggesting causality between smoking and increased MS risk.

The association between the pathogenesis of MS and cigarette smoking appears to be modulated by the immune system, in addition to smokings neurotoxic effects. A proinflammatory cascade is induced by cigarette smoke and continues throughout the respiratory system, subsequently culminating in the lungs. Ultimately, macrophages release cytokines and free radicals that damage the surrounding alveolar epithelium. Inflammation and immune cells within the lungs also contribute to autoimmunity, driving the risk for MS in people who smoke.

Free radicals and cyanide present in cigarette smoke lead to damage to the mitochondria, which may result in severe damage to myelin. Smokes neurotoxic effects may also contribute to worsening disease prognosis in patients with MS who smoke. Additionally, studies have linked cigarette smoking with greater lesion loads on MRI scans in patients with MS as well as clinically isolated syndrome. Concerning findings in other studies suggest that cigarette smoke may adversely affect the efficacy of disease-modifying therapies, such as natalizumab.

While electronic cigarettes have not been extensively studied in regard to their effects on MS risk, researchers have alluded that heated vapor in these devices may be just as harmful as tobacco combustion and may also contribute to the pathogenesis of the autoimmune disorder.

The authors of the review added that the pathways involved in smoking may be implicated in other environmental exposures (eg, organic solvents) and health habits (eg, waterpipe smoking), in addition to tobacco smoke.

Researchers note that in terms of MS risk, increased risk persists after smoking cessation. However, smoking cessation decreases future risk of MS progression and accrual of disability burden. As such counseling is key in supporting patients with all patients, especially those with MS, before and during smoking cessation.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Rosso M, Chitnis T. Association between cigarette smoking and multiple sclerosis: a review [published online December 16, 2019]. JAMA Neurol. doi: 10.1001/jamaneurol.2019.4271

Excerpt from:
Review Highlights the Importance of Smoking Cessation in Patients With Multiple Sclerosis - Neurology Advisor

Special Journal Issue on Functional Neurological Disorder Brings Attention to a Neglected Field: Investigator Q&A – Psychiatry Advisor

The latest issue of The Journal of Neuropsychiatry & Clinical Neurosciences (JNCN) focuses on Functional Neurological Disorder (FND), a neuropsychiatric condition with significant physical and mental health features. Psychiatrists commonly refer to this condition as Conversion Disorder, whereas neurologists may be more familiar with terms such as functional movement disorders and dissociative seizures, among other subtypes of FND.

Largely understudied until recently, FND presents a critical challenge to practitioners in neurology and psychiatry. Furthermore, the complex issues faced by patients require evidence-based approaches to both treatment and the medical communitys fundamental understanding of the disorder. In light of these challenges, the 5 guest co-editors of the special issue David L Perez, MD, MMSc, Selma Aybek, MD, Timothy R Nicholson, MD, PhD, Kasia Kozlowska, MBBS, PhD, W Curt LaFrance, Jr, MD, MPH put together a series of articles touching on risk factors, treatment approaches, and outcome measures, among other key topics. Psychiatry Advisor contacted Dr Perez and Dr Nicholson to discuss the special issue of JNCN and the state of the field.

Psychiatry Advisor: In your view, what is the significance of this special issue, the first published on FND in nearly 2 decades?

David Perez, MD, MMSc: This special issue on FND is a landmark event for the field. FND is among the most common conditions encountered by neurologists and neuropsychiatrists, yet because this diagnosis falls at the borderland between neurology and psychiatry, it has not had the clinical, academic, and research attention it deserves.

Over the last few decades, there have been significant breakthroughs in evidence-based diagnostic and treatment approaches, as well as the development of an improved understanding of disease mechanisms, resulting in renewed interest in FND across the clinical neurosciences. This progress is exemplified by the broad range of articles within our special issue on FND.

Psychiatry Advisor: How has our understanding of FND changed since the formative era of modern neuropsychiatry in the early 20th century?

Dr Perez: It is important to highlight that FND, previously termed hysteria and synonymous with Conversion Disorder, was of great interest to early pioneers in psychiatry and neurology, including Charcot, Freud, Janet, Babinski, and others. One of the major hopes of this special issue is that this effort will energize clinicians and researchers across the clinical neurosciences to care for and develop cutting edge research in this underserved population.

Foundational to our modern framing is the notion that FND is a neuropsychiatric disorder at the intersection of the mind and the brain. According to our perspective, this condition is brain-based and neural circuits do not artificially divide into neurological circuits and psychiatric circuits. An integrated, interdisciplinary approach that embraces neurologic, psychiatric, psychological, and rehabilitation perspectives is the present and future of FND clinical and research efforts.

Additionally, it is now recognized that there are a number of predisposing vulnerabilities or risk factors for the development of FND, and adverse life events may have etiological relevance for some but not all patients. This point is nicely exemplified by Professor Jon Stone and colleagues in their study of individuals with functional limb weakness, which notes that only about a third of patients in their sample reported childhood abuse and/or neglect.1

Psychiatry Advisor: In a recent article, an international panel of experts was organized to discuss the complexities of developing outcome measures for FND.2 Why is this an important issue in the field?

Timothy Nicholson, MD, PhD: With the long overdue growth of both clinical service provision for FND and research into its treatments comes a need to optimize outcome measurements to monitor changes in symptoms. Designing and selecting outcome measures is a complex task for any disorder, but there are particular features of FND that make this even more complex. These features, such as the wide variety of symptoms in FND and the potential for subjective rather than objective measures to be of more relevance than in other disorders, are discussed in this perspective article from a panel of 45 experts from 13 countries that aims to drive forward consensus and development of outcome measures in FND.

Psychiatry Advisor: What does FND tell us about the divide between mental and physical health?

Dr Nicholson: FND is the quintessential disorder through which to understand and conceptualize that mental and physical health are inherently intertwined, and any divide is an illusion that hinders both research and clinical care for mental health disorders, neurological disorders, and those in between. Patients with FND present with neurological symptoms that can resemble almost all other neurological disorders, but remain discernable by distinct clinical examination features (so-called positive signs).

The condition also has complex interactions with psychological processes (such as dissociation) and psychological disorders (such as PTSD and panic attacks) that have led to the traditional dominance of psychological models of the disorder. However, such models must of course be rooted in neurological (or brain-based) dysfunction, albeit at a complex multi-network level. There are exciting new theories, such as Bayesian computational models for motor and sensory dysfunction in FND that point the way forward for neuroscientific approaches. These models integrate mental and physical functions, ignoring the mirage of any false divide between them.

Psychiatry Advisor: Your editorial mentions the feasibility of implementing physical therapy for motor FND. Can you highlight other specialties outside of neurology and psychiatry that would benefit patients with FND?

Dr Perez: In addition to neurologists and psychiatrists, optimal care often involves physical therapists, occupational therapists, speech and language pathologists, psychologists, and/or social workers, among other disciplines. This interdisciplinary approach to FND is highlighted by the tree diagram that appears on the cover image for our special issue.

Psychiatry Advisor: The special issue includes an article detailing the establishment of specialized FND clinics in the United Kingdom, Switzerland and Canada. What does quality care for patients with FND currently look like?

Dr Perez: While FND care will certainly require robust engagement with general neurologists and psychiatrists, it is also encouraging that both here in the United States and internationally, such as in the United Kingdom, Switzerland, and Canada, subspecialty FND clinical programs have been developed. The article by Dr. Selma Aybek, one of the guest co-editors for this special issue, highlights the potential role of outpatient subspecialty FND clinics.3 Their roles include providing diagnostic clarification in challenging cases, as well as helping patients connect to evidence-based treatments, such as motor retraining and psychological treatments, particularly cognitive behavioral therapy.

Psychiatry Advisor: Patients with FND present with a wide variety of symptoms and comorbidities. In the context of such heterogeneity, how should clinicians approach treatment strategies?

Dr Perez: From a treatment perspective, the special issue adds to an emerging new outpatient model of care emphasizing roles for diagnostic clarification,3 treatment using cognitive behavioral therapy,4 and motor retraining as part of FND-specific physical therapy.5

Psychiatry Advisor: As you noted in your editorial, FND receives little attention, but when it does, it frequently arises as a medical mystery in stories of mass psychopathology, most recently in the case of the US embassy in Cuba. How can physicians and advocates bring attention to the far more common experiences of the patients you see on a regular basis?

Dr Perez: Indeed, FND is often hiding in plain sight, as illustrated in the article6 by Dr Popkirov and colleagues, which provides evidence that some popular news stories on medical mysteries can be reliably identified as cases of FND on the basis of positive signs of functional movement disorders or dissociative seizures. This phenomenon illustrates the critical importance of training clinicians across disciplines in the diagnosis of FND, including the delivery of the diagnosis in a way that patients can understand and accept, as well as increased awareness and understanding of the disorder among the general public. We hope that public awareness will improve and medical research funding will expand for this underserved population through academic efforts such as this special issue, educational initiatives on FND in medical school and residency training settings, and patient advocacy through organizations such as FND Hope and FND Action. The newly formed FND Society will have its inaugural conference this summer in Boston, which will include a strong training component for all relevant clinicians and scientists who want to learn more about this important, yet poorly understood, disorder.

References

Original post:
Special Journal Issue on Functional Neurological Disorder Brings Attention to a Neglected Field: Investigator Q&A - Psychiatry Advisor

Atrius Health announces new board members – The Item – Newton TAB – Newton, MA – Wicked Local Newton

Atrius Health announced Karen DaSilva, Bonnie Hersh and Kathy Niknejad as new members to its board of trustees and the reelection of Joo Kim to the board.

Atrius Health physicians elect physician trustees to the board, representing Atrius Healths commitment to the strength of provider-patient relationships and providing the right clinical care.

Our incoming board members exemplify the compassionate and coordinated care we strive to deliver each of our patients, said Steve Strongwater, president & CEO of Atrius Health. They also offer impressive clinical leadership in primary and specialty care across our practice. We are pleased to welcome new and existing members to the board, and we look forward to working together to advance our mission to provide high quality, patient-centered and cost effective care to everyone we serve.

DaSilva, a resident of Sudbury, has served as a primary care internist at Atrius Healths Harvard Vanguard Medical Associates Chelmsford practice since 1994. Over the years, she has taken on several leadership roles including vice president of innovation at Atrius Health. In this role, DaSilva helped in developing improved care delivery models to meet the low-cost, high quality care demands of the current healthcare environment. In addition, she served as the organizations specialty director for internal medicine, where she oversaw the delivery of primary care across more than 20 practice sites.

DaSilva also served as deputy chief medical officer of Harvard Vanguard Medical Associates, where she led the development of a new geriatric care model and several disease management programs. She spearheaded the practices early work in the development of a patient-centered medical home program, which ultimately led to Atrius Healths primary care practices receiving Level 3 Patient-Centered Medical Homes from The National Committee for Quality Assurance. She received her medical degree from Albany Medical College and completed her internship and residency at Albany Medical Center Hospital in New York. DaSilva is board-certified in internal medicine and hematology.

As chief of neurology at Atrius Health, Hersh leads Atrius Healths neurology department and has worked at Atrius Health since 2000 when she joined its Harvard Vanguard Medical Associates practice. She is board certified by the American Board of Psychiatry and Neurology.

Hersh attended medical school at McGill University in Montreal and did her internship at Cedars Sinai Medical Center in Los Angeles. She completed her neurology residency at Harvard Medical Schools Harvard-Longwood Neurology Training Program. She then completed fellowship training in movement disorders at Boston Medical Center and neurophysiology/EMG at Massachusetts General Hospital. Prior to joining Atrius Health, Hersh was on the neurology staff at Boston Medical Center.

As chief of urology at Atrius Health, Niknejad leads Atrius Healths urology department and has worked at Atrius Health since 2004 when she joined Harvard Vanguard Medical Associates Chestnut Hill/West Roxbury and Kenmore practices. After joining Harvard Vanguard, she served as its surgical specialties medical director for four years. During that time, she also served as the practices Chief of General Surgery and Urology.

Niknejad is a board-certified urologist. She received her undergraduate degree from San Diego State University and graduated from Harvard Medical School. Niknejad completed her internship and residency at Brigham and Womens Hospital and is an instructor in surgery at Harvard Medical School. Niknejad is a resident of Weston.

Kim, a resident of Belmont, serves as associate chair of Atrius Healths internal medicine service line and has worked as a primary care internist at Atrius Healths Harvard Vanguard Medical Associates practice in Watertown since 2003. She enters her second term as a board clinician trustee.

Kim received her medical degree from The Robert Larner, M.D. College of Medicine at The University of Vermont and completed her undergraduate education at Brown University. She completed her internship and residency at Cambridge Hospital in Massachusetts and is board certified by the American Board of Internal Medicine.

Read more here:
Atrius Health announces new board members - The Item - Newton TAB - Newton, MA - Wicked Local Newton

Risk Factors Are Frequently Inadequately Treated in Patients With Stroke or TIA – Neurology Advisor

In patients with ischemic stroke and transient ischemic attack (TIA) there is a significant gap between evidence-based cerebrovascular risk factors control and real-world stroke prevention, according to study results published in Neurology.

Whileprevious studies have found poor lifestyle and modifiable risk factors arecommon in patients with ischemic stroke, limited data are available on riskfactor control in patients with stroke/TIA.The goal of the study was to assess the prevalence of inadequatelytreated risk factors in a large cohort of patients with stroke/TIA.

The observational cohort study included patients from the Poststroke Disease Management STROKE-CARD trial (ClinicalTrials.gov Identifier: NCT02156778). Of 2625 adult patients with acute ischemic stroke or TIA admitted to the University Hospital Innsbruck, Austria, between January 2014 and December 2017, the study population comprised 1730 patients (median age 72 years, 59.6% men), including 1424 stroke patients and 306 patients with TIA. Of these, 1382 were first-ever strokes/TIAs.

Overall,79.5% of subjects had at least one inadequately treated stroke risk conditionbefore the index event. Hypercholesterolemia (53.4% of the study population)and hypertension (45.7%) were the most common risk factors, followed by atrialfibrillation (12.5%), previous atherosclerosis cardiovascular disease (12.4%),diabetes mellitus (9.9%), unrecognized TIA (2.7%), carotid stenosis (2.1%), andmechanical heart valves (0.5%).

Whenmodifiable lifestyle risk behaviors were included as inadequately-treated riskfactors, the percentage of subjects with at least 1 inadequately treated strokerisk condition before the index event was 95.1%. Many subjects had more than 1uncontrolled risk factor (eg, 72.3% had at least 2 inadequately treated riskfactors).

Thenumber of inadequately treated risk factors was higher in patients withrecurrent stroke/TIA, compared with patients with first-ever events (P <.001),in younger patients (75 years) compared with patients >75 years of age (P<.001), and in male patients (P =.003).

Assessmentof stroke preventability with adequate risk factors control revealed that bloodpressure control could have prevented 237 events (13.7%), while rigorous lipidprofile control could have prevented 182 events (10.5%) and properanticoagulation in patients with pre-diagnosed atrial fibrillation could haveprevented 145 events (8.4%). On theother hand, the estimated degree of stroke preventability with adequateanticoagulation in patients with mechanical heart valves was low (0.4%).

Forthe 5 most relevant risk factors combined (hypertension, hypercholesterolemia, atrialfibrillation, smoking, and overweight), the estimated degree of strokepreventability was 1 in 2, assuming an additive effect, and 1 in 4 with ahighly conservative computation approach.

Thestudy had several limitations, according to the researchers, including lack ofconsensus on the definition of adequate control of risk factors, missinginformation on pre-stroke blood pressure profiles, lack of valid way to assessthe quality of diet and physical activity.

Population-widecampaigns, individualized prevention and poststroke disease managementprograms, and an increased awareness among physicians about the concept ofstroke preventability are required to reduce the global burden of stroke,conclude the researchers.

Reference

Boehme C, Toell T, Mayer L, et al. The dimension of preventable stroke in a large representative patient cohort. [published online Oct 31, 2019]. Neurology. doi:10.1212/WNL.0000000000008573

Go here to see the original:
Risk Factors Are Frequently Inadequately Treated in Patients With Stroke or TIA - Neurology Advisor

Omarosa: Something Neurological Going on with Trump His Ignorance Is Destroying America – Breitbart

Former Apprentice cast member and former White House staffer Omarosa Manigault Newman declared on Sundays broadcast of MSNBCs Weekends there was something neurological going on with President Donald Trump.

Manigault Newman said, I think its time for us to ring the alarm that Donald Trump is dangerous, and he is damaging our democracy.

She added, There is something neurological going on with Donald Trump. I am not a doctor, but Ill tell you what I observed in 2003 when I first met the man and when I last spoke to him. There is some disconnect with his ability to process basic information. Its not that he doesnt know the basic terminology of the government, of its structure and functions. He makes statements that have impact around the world. Thats what he doesnt grasp. His ignorance is destroying our country.

Follow Pam Key on Twitter @pamkeyNEN

Continued here:
Omarosa: Something Neurological Going on with Trump His Ignorance Is Destroying America - Breitbart

Exicure Announces First Neurological Development Program in Friedreich’s Ataxia and Expands Scientific Advisory Board – Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced Friedreichs ataxia (FA) as the therapeutic indication for the companys first neurology development program. Exicure also announced the expansion of its Scientific Advisory Board.

Over the past year Exicure has developed extensive preclinical data supporting the development of our SNAs for neurological disorders. Were eager to evaluate our technology for this important unmet medical need, said David Giljohann, PhD, Exicures chief executive officer. We are also pleased to add the experience and team from the Friedreichs Ataxia Research Alliance (FARA), added Dr. Giljohann.

Patients living with FA experience a devastating and progressive loss of neurological function. There are no approved therapies for FA. Exicures FA program will be designed and developed with guidance from and in collaboration with FARA.

"FA is a rare, progressive and life-shortening disease, and there is a critical need for effective treatments," explained FARA's Chief Executive Officer, Jennifer Farmer. "Exicures SNA technology is unique in its ability to target the affected gene in FA. FARA has championed collaborative approaches to drug development, and were thrilled to work with Exicure as they develop their genetically targeted therapeutic candidate.

Exicure expects IND-enabling work to begin in 2020. Exicures preclinical data in rodents and non-human primates showed distribution of SNAs to all brain regions following intrathecal administration, including those relevant in FA. Additional preclinical rodent data, in a head-to-head comparison with an FDA-approved oligonucleotide, nusinersen, showed improved potency in mice when put into an SNA format.

Exicure also is announcing the expansion of the companys Scientific Advisory Board to include neurology experts Dr. Susan Perlman, MD, Professor of Neurology at University of California Los Angeles and Medical Director for the National Ataxia Foundation and Dr. Hank Paulson, MD, PhD, Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan.

We are pleased to bring together this fantastic group of patient advocates, medical leaders, and disease experts to join the Exicure team in our mission to launch a program in Friedreichs ataxia, Dr. Giljohann concluded.

About Friedreichs Ataxia (FA)

FA is a rare, degenerative, life-shortening neuro-muscular disorder that affects children and adults, and involves the loss of strength and coordination usually leading to wheelchair use; diminished vision, hearing and speech; scoliosis (curvature of the spine); increased risk of diabetes; and a life-threatening heart condition. There are no FDA-approved treatments. An estimated 5,000 patients in the US and 15,000 patients worldwide are affected by FA.

About FARA

The Friedreich's Ataxia Research Alliance (FARA) is a 501(c)(3), non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for Friedreich's ataxia. http://www.CureFA.org

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA.

For more information, visit Exicures website at http://www.exicuretx.com.

Exicure Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Companys technology, potential therapies and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, plan, believe, intend, look forward, and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicures pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Furthermore, data from preclinical studies in mice often fails to be indicative of outcomes in human trials. Risks facing the Company and its programs are set forth in the Companys filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

More:
Exicure Announces First Neurological Development Program in Friedreich's Ataxia and Expands Scientific Advisory Board - Business Wire

Scientists Have a Fascinating New Map of the Human Brain on DMT – VICE

Taking DMT is a bit like putting your brain through a jet engine and getting your consciousness blown out the other side. Theres no you anymore. Youre just kind of everywhere, surrounded by colours and fractals and aliens that look a bit like elves. It feels a lot like being dead, or what you imagine being dead feels like, and then youre sucked back into your body feeling somewhere between terrified and peaceful. But whats weird is that for such a chaotic ride, there seems to be a pattern to the experience. The trip tends to follow a similar trajectory each time, and everyone seems to experience some variation of the same thing.

For scientists this uniformity presents some interesting questions. Namely: whats the neurology behind DMT? And why do so many people report seeing elves? These questions have instigated a few studies, including one at Johns Hopkins in the United States, but the latest findings have just come from the Imperial College London.

Last week a study published in Scientific Reports looked at the brains response to DMT, courtesy of the colleges Psychedelic Research Group. There, researchers administered intravenous DMT to 13 subjects, while measuring their brains electrical activity via a web of electrodes loaded into head capsdevices that are known as "EEG caps".

If were serious about understanding human beings and their consciousness, we need to understand psychedelic experiences, Christopher Timmins, a PhD student at Imperial College London and author of the study, told VICE over the phone. DMT [is] particularly relevant because, at normal doses, it generates this very strong sense of immersiveness.

We asked Christopher what else he and his team discovered about DMTs bewildering effects on the brain.

Christopher Timmermann. Credit: Imperial College London, photo by Thomas Angus

VICE: HI Chris. Can you start by explaining our current understanding of how DMT works on a neurological level?Christopher Timmermann: We know DMT works with the serotonin system in the brain. Serotonin is one of the major chemicals that we have in the brain thats responsible for a series of functions related to consciousnesswakefulness, attention. DMT is very closely related to the serotonin molecule. We also know that if you block a specific serotonin receptor in the brain, the psychological effects of DMT are inhibited. So we know that the specific receptor, the serotonin 2A receptor, is crucial for psychedelic effects. And this receptor is expressed all over the cerebral cortexits very prominent in sensory areas, and its distributed all around.

What neurological effects did you see in your subjects after theyd taken DMT? The brainwave patterns seen are particularly notorious in certain states of consciousness. For example, you have an Alpha wave pattern thats very prominent when you close your eyes and disengage from the environment. When we open our eyes after that, this Alpha wave pattern goes down a very significant way. In the DMT study, we found the same thinga very strong reduction of these Alpha waves. The only difference is that people kept their eyes closed. It's almost as if people were seeing with their eyes closed, engaging with a world. And we found this reduction in Alpha waves was very strongly associated [with] the intensity of the experience.

Another way we try to understand brain activity is to see how chaotically, or entropically, the brain behaves after we administer these drugs. With DMT, we found that there was a huge increase in this chaotic activity. This is interesting because its the opposite of what happens in the brain when there is a loss of consciousness, such as when youre in a coma, or youre sleeping or dreaming.

Were there any other brainwave patterns you noticed?Yeah we also saw an increase in Theta and Delta waves. Its interesting because these increases were particularly noticeable when people were in the peak of this experience, so the moment in which people felt completely immersed in this alternate reality of sorts. This Theta wave, specifically, is tightly related to dreaming, so therefore we have some initial evidence that theres a similar mechanism behind dreaming and this very immersive DMT experience.

Treatment room setup. Credit: Imperial College London and photo by Thomas Angus

Im interested in how the people in your study reacted to the DMT. You write that they were all exposed to psychedelics, but did anyone report seeing anything interesting during their trip?There were challenging moments for sure; moments where people in the interview after reported that it was too much. One participant said she reached a point in which she couldnt go further. She described encountering some beings or entities that were pushing against her, not allowing her to trespass into their realm, and I think this was particularly challenging. But after that, she said she was falling through pink clouds of comfort, and other entities were healing her once she was going through this space.

Now, the whole idea is DMT allows people to break through different realities. But it's fairly well established that while some can, others cant. Is there any neurological reason as to why this is?There are many factors that can influence this. Id say a very important one is that people usually smoke DMT, and smoking is a very ineffective way to ingest a drug because a lot of the product can be burned before its absorbed. Theres variability in the lung capacity people have, how much time theyre holding the smoke in, and basically, your history with smoking other substances.

Okay, but are there any explanations neurologically? You mentioned serotonin earlier, so could anything be altering those receptors, like antidepressant drugs for example? We dont know how well antidepressants interact, at least at the experiential level. The usual saying of psychedelics is that when people are taking antidepressants, psychedelics dont work as well. Theres also some evidence that this serotonin 2A receptor is mediated by a gene some people apparently have or dont have. But again, these things are speculative. Theres nothing mechanistically proven about why people may not break through. But I would say that dose is a very big explanation.

Is there any scientific way to explain DMT breakthroughs? Like, are we closer to understanding why, or how, people meet entities like machine elves?At the moment we dont know. What were doing now is were conducting other experiments in which we use DMT, and we give it inside fMRI scanners, because fMRI scanners allow you to look at things happening [inside] the brain with much more precision. And that is important because we know that certain areas of the brain are used for recognising faces, when were engaging in social activities, and so on.

So youre saying DMT might affect the parts of our brain that recognise faces, which could be why were seeing the faces of elves when were on DMT? Look, DMT might be acting on specific areas of the brain responsible for face recognition, or understanding the mind of others, or recognising intentions, but these are speculations only.

So, to you, whats been the point of the study? How has this research helped us to understand DMT or even this notion of consciousness? An important part of this study has been exploring how DMT trips are part of the human experience repertoire. These are states that human beings can have. As a scientist, theres a natural curiosity in understanding not only why, but understanding the experiences themselves. One of the important things about this study has been examining what kind of experiences human beings can have, and how we can make sense of them.

Interview by Sam Nichols. He's on Twitter

This article originally appeared on VICE AU.

Follow this link:
Scientists Have a Fascinating New Map of the Human Brain on DMT - VICE

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Scl | PROM – Dove Medical Press

Osman Ozel,1 Caila B Vaughn,1 Svetlana P Eckert,1 Dejan Jakimovski,2 Alexis A Lizarraga,1 Bianca Weinstock-Guttman1

1Jacobs MS Center for Treatment and Research, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA; 2Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA

Correspondence: Bianca Weinstock-GuttmanJacobs MS Center for Treatment and Research, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, 1010 Main Street, 2 nd Floor, Buffalo, NY 14202, USATel +1 716 829 5063Fax +1 716 829 4001Email bw8@buffalo.edu

Abstract: Dimethyl fumarate (DMF) is a commonly prescribed oral medication for the treatment of relapsing forms of multiple sclerosis (MS) with a wide range of hypothesized downstream mechanisms of action. Randomized clinical trials have established its clinical efficacy by using standard objective clinical measures. However, MS is a chronic disease that, apart from physical ailments, can affect an individuals mood, psychosocial status, and quality of life which cannot be captured by using only objective assessment tools. Given the challenge of determining the efficacy of the treatment in a real-world clinical setting, the use of patient-reported outcomes (PROs) may help us to better address these aspects of patient care and establish a more patient-centered approach to MS care. To date, a review of PubMed identified six studies which reported on PROs in patients who are taking DMF. In total, twelve different kinds of PRO measures were utilized and 6359 patients provided at least one form of PRO in these studies. Upon review of these studies, we were able to conclude that people with MS had decreased quality of life compared to the healthy population in the US. MS patients on DMF, however, had better health-related quality of life assessment scores compared to those using a placebo. Previous studies also suggested that DMF decreased work productivity impairment scores after one year of use compared to baseline. DMF was associated with less impairment in fatigue and depression scales along with improved treatment quality assessment and adherence scores. This review will present a brief synopsis of the published literature and will provide indications for future directions with respect to PROs and DMF in people with MS.

Keywords: multiple sclerosis, patient-reported outcomes, outcome measures, quality of life, dimethyl fumarate

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More here:
Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Scl | PROM - Dove Medical Press

American Headache Society Publishes Article Demonstrating the Promise of Remote Electrical Neuromodulation (REN) as First-Line Treatment for Acute…

NETANYA, Israel, Nov. 8, 2019 /PRNewswire/ --Theranica Bio-Electronics Ltd., a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today that the American Headache Society published an article in its peer-reviewed journal, Headache: The Journal of Head and Face Pain, highlighting the promise of Remote Electrical Neuromodulation (REN) as an alternative to current treatment options and as a potential first-line therapy for acute migraine relief.

"While migraine is one of the most prevalent and disabling neurological diseases affecting a significant portion of the global population, many are still looking for an effective, long-term treatment option," said Alan Rapoport, M.D. author of the article and Professor of Neurology at UCLA. "For the first time, REN offers an effective, safe and non-invasive alternative for acute migraine treatment and may be suitable as a first-line therapy for some users."

The article Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine, reviews a pilot study and a pivotal study conducted to determine the safety and efficacy of the Nerivio, Theranica's smartphone-connected prescription migraine wearable device. Both studies showed positive results, demonstrating REN is as effective a treatment for acute treatment of migraine as standard pharmacological treatments, with a favorable safety profile.

The Nerivio alleviates migraine symptoms by stimulating the body's Conditioned Pain Modulation (CPM) response, in which one painful stimuli modulates pain in other regions of the body. As a smartphone-connected wearable, users can individually control the strength of their therapy and easily share data collected with healthcare providers to improve treatment plans.The Nerivio is the first device to use REN to stimulate CPM by placing the device on the upper arm at the onset of a migraine episode.

"The future of migraine care lies in non-invasive, drug free technologies that are effective and affordable," said Alon Ironi, CEO and co-founder of Theranica. "For those living with migraine, the search for long-term symptom relief is not easy. REN opens the door for new therapeutic alternatives, with Nerivio leading the way."

The article will be published in Headache's print journal in the coming weeks.

About Theranica

Theranica Bioelectronics, founded in 2016, is dedicated to combining advanced neuromodulation therapy with modern wireless technology to develop proprietary electroceuticals that address prevalent medical conditions and diseases. Nerivio, Theranica's first FDA authorized to market device is a low-cost, low side effect wearable for the acute treatment of migraine. Theranica will continue to use its proprietary technology to develop additional solutions to other painful disorders.

For more information about the Nerivio, including Indication for Use, and Important Safety Information, visitwww.theranica.com.

FollowTheranicaonTwitterandLinkedIn.

Media Contact:Ellie HansonFinn PartnersEllie.Hanson@finnpartners.comTel: +1-929-222-8006

Theranica Contact: Ronen Jashekronenj@theranica.comTel: +972-72-390-9750

View original content:http://www.prnewswire.com/news-releases/american-headache-society-publishes-article-demonstrating-the-promise-of-remote-electrical-neuromodulation-ren-as-first-line-treatment-for-acute-migraine-relief-300954693.html

SOURCE Theranica

More here:
American Headache Society Publishes Article Demonstrating the Promise of Remote Electrical Neuromodulation (REN) as First-Line Treatment for Acute...

‘Text neck’ injury becoming more common in kids, teens – KPAX-TV

OVERLAND PARK, Kan. Fall can be a busy season for sports medicine physicians as school sports ramp up.

"People come in with neck pain, they come in with upper back pain," said Dr. James Roberson of Children's Mercy Kansas City.

But those neck and back injuries often have nothing to do with sports.

"A lot of kids are kind of thinking 'oh there's no way that just looking at my phone is the problem here,' " Roberson said. "For the parents, it takes zero convincing."

The repetitive strain injury is known as "text neck."

"Sometimes I even have to lay down because my neck hurts, so I'll lay and type out a text or something," said college student Lauren Juliana.

The average head weighs 10 to 11 pounds, according to a study published in Surgical Neurology International. When you flex your head forward 30 degrees to look down at a phone, the strain on your neck is actually 40 pounds. At 60 degrees, you put 60 pounds on your neck.

"The more you do it, the more it will hurt, the harder it is to break that habit," Roberson said.

But you don't have to keep sticking your neck out to stay in touch with your friends. One easy fix is to raise your screens to eye level.

"I recommend that kids, if they're working a lot on an iPad, that they actually get a cookbook stand and set it up on a few books," Roberson said.

You can even stretch to alleviate the pain.

Roberson demonstrated one stretch in which you grab the sides of your chair then tilt your head left and right.

Another exercise he suggested is probably best to do when you're alone.

"I call it the 'derp stretch' because it makes you look kind of stupid," Roberson said with a laugh.

Start with your chin in a neutral position, then push it straight back, stretching out the back of your neck.

You can also do simple shoulder pinches to release tension. Roberson recommended doing ten repetitions of the exercises three times a day.

He's also giving parents the green light to nag their kids about the bad habit.

"It's good to tell your kids to sit up straight, better posture, move the screen up or get off the screen, go outside and play instead, which is always good advice," Roberson said.

This story was originally published by Cat Reid on KSHB.

Continue reading here:
'Text neck' injury becoming more common in kids, teens - KPAX-TV

Department of Neurology – University of Texas Medical Branch

A Message from the Departmental Chair

The Department of Neurology at University of Texas Medical Branch (UTMB) was established in 1973. It has a long-standing history and tradition in the practice and advancement of Clinical Neurosciences by providing the most comprehensive care to patients with neurologic illnesses from Alzheimers disease and related dementias, epilepsy, neuromuscular disorders, brain tumors, Parkinsons Disease and other movement disorders, multiple sclerosis and other autoimmune disorders, stroke as well as other acute neurologic injuries. Our department has a robust laboratory research program in the Mitchell Center that is particularly focused at advancing our knowledge of neurodegenerative disorders. Additionally, we have a highly regarded fully-accredited neurology residency training program that has served for highly successful career trajectories for our graduates.

The values of the department are aligned with the mission of UTMB to uphold integrity, demonstrate compassion and respect, embrace diversity, and strive for excellence and innovation. The departmental philosophy and vision is to optimize an organizational environment that strives for excellence in the domains of: a) clinical patient care; b) teaching, training, and mentoring medical students, residents, fellows, faculty, and staff; and c) research and scholarship. Our overall goal is to continue providing state-of-the-art care to patients with neurologic disorders, conducting and enhancing research (clinical, translational, and basic science) through interdepartmental collaborations, and training the next generation of neurologists and neuroscientists to improve diagnosis, and management of neurologic disorders and to develop more innovative therapies and strategies for the future.

Sincerely,

Anish Bhardwaj, M.D., M.B.A.,CPE, FACMPE, FACHE, FAHA, FCCM, FAAN, FANAChairman, Department of NeurologyJohn Sealy Chair of NeurologyProfessor, Neurology, Neurosurgery, Neuroscience, Cell Biology and AnatomyAssociate Dean for Faculty Affairs and Professional Development

University of Texas Medical Branch (UTMB)9.128 John Sealy Annex, Route 0539301 University BlvdGalveston, Texas 77555

Go here to read the rest:
Department of Neurology - University of Texas Medical Branch

Highlights from Day Four of the World Congress of Neurology 2019 – WFN News

Report byProf. Tissa Wijeratne MD FRACP FRCP (Edin) FRCP (London) FAHA FAAN (USA)

It had been a fabulous 24th World Congress so far. The diversity of the speakers and delegates continue to make the world congress the premier event in neurology. The day began with an enlightening teaching course on neuro-imaging with a packed audience.

Professor John Hardy from UCL, Institute of Neurology answered the following question with a masterful lecture:What is genomics teaching us about neurodegeneration and what should we do about it?"

Prof. Hardy went on to address the issue in detail. As researchers identify the loci involved in neurodegenerative disease, they are finding that the majority of them are involved in damage response processes. He went on to propose that it is a failure in these damage response processes which underlies late-onset disease and that the resultant pathology is a marker of the type of damage response which has failed. He gave the following three examples.

He gave a detailed analysis of these and asked the question, with this insight how we could go about understanding and treating these diseases better?

The plenary gave us a ray of hope for future therapeutic potential for these disabling diseases.

Professor Tintore from Spain delivered the second plenary on multiple sclerosis. The plenary explained the evolution of diagnostic criteria for MS with McDonald 2001, 2005, 2010 and 2017 allowing earlier diagnosis with less active disease. Major advances in therapies, the importance of other factors such as lifestyle, comorbidities were discussed in detail.

Professor Reis and Wasay chaired the all-important environment and neurology symposium.

Air pollution as a major risk factor for stroke was discussed in detail. Professor Gustavo Roman discussed the environmental neurotoxins in food.

The Tournament of the minds semi-finals were extremely competitive with a tie-break between Sri Lanka and Australia. I was reminded of the 1996 world cup cricket to say the least!

Sri Lanka, Malaysia, India and Hong Kong will be fighting for the final countdown next!

See the article here:
Highlights from Day Four of the World Congress of Neurology 2019 - WFN News

Neurology Software Market Perceive Robust Expansion by: Epic, Bizmatics, Athenahealth, healthfusion, Allscripts – New Day Live

Neurology Software market report forecast include the rapid expansion of current market it also shares the market prediction within a specific interval to time. To provide better perspective of the market report gives detail analysis of drivers, restraints, and trends that control the present market scenario. While classifying these segments, the specialist team of analysts has listed the relative impact of each segment for the growth of the Neurology Software market report. Neurology Software Market Report also provides independent analysis of the basics concepts of Neurology Software market.

Each segment of Neurology Software market report offers a in-depth information with qualitative and quantitative analysis of the market. Neurology Software market report also presented the value of absolute dollar opportunity for all the segments over the predicted period of 2020 to 2025.

Get Sample Report @ https://www.reportsintellect.com/sample-request/990040

Major market player included in this report are: Epic, Bizmatics, Athenahealth, healthfusion, Allscripts

Neurology Software Market Key segments:

By type:

Advanced Neurology EMR SoftwareOther

By Application:

HospitalsCollege & Research InstitutesOther

Neurology Software Market report provides the Split of the regional market into specific countries as per your research requirements. Also Neurology Software Market report has presented the various facets of the market with a particular focus on identifying the key industry influencers.

Research report reviews Neurology Software Market Report volume in recent years. The report also emphasizes the major restraints and drivers determining the growth of the market. A report also highlights market factors like latest trends and opportunities.

Get Discounted Report @ https://www.reportsintellect.com/discount-request/990040

Details to look for in the Report:

Report offers definition and outline of Neurology Software Market with geographical dynamics that can set the Neurology Software market sky scrapping. This geographical segmentation clearly helps understand the growth and development of the Neurology Software Market in various regions from across the globe. The clarification of the historic, present, and future trends along with various competitive factors and restrictions shows the impact of these on the development of the Neurology Software market. Moreover, the report furthermore contains contributions from our exchange experts that may encourage the key players in sparing their time from the inside examination half.

Report Highlights:

1) Strategic recommendations in key business segments based on the market estimations.

2) The report provides a detailed analysis of current and future market trends to identify the investment opportunities.

3) Breakdown of the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2020 to 2025.

4) The details of the competitive landscape.

5) Top key market players and their complete profiles

6) The restraining factors coupled with the challenges being faced by the market players are included within the Neurology Software market report.

Follow this link:
Neurology Software Market Perceive Robust Expansion by: Epic, Bizmatics, Athenahealth, healthfusion, Allscripts - New Day Live

Nerve Repair Biomaterial Market to Witness Speedy Development Owing to Greater Frequency of Neurological Complaints and Nerve Injuries by 2028:…

SAN FRANCISCO, March 11, 2020 /PRNewswire/ -- The global Nerve Repair Biomaterial Market is estimated to grow at a higher CAGR by the completion of the prediction period. The nerve repair biomaterials are utilized for reinstating damaged nerves. Injuries to the nerve take place in the lower (leg) and upper (hand and arm) edges. Biomaterials are prepared with nerve wraps, nerve protectors, nerve connectors, and nerve conduits. Owing to the high blood pressure (Diabetes), sharp or blunt trauma, the damage to the nerve happens. Nerve repair is the restoration of the nerve that is hurt. The nerve repair biomaterials are utilized to reinstate the usual working of nerves.

The bodily harm to an exterior nerve or else the incapability to appropriately rejoin nerves can result in the loss of muscle sensation/function. Nerves can be injured by numerous means. Once a nerve is cut owing to a stressful injury or surgical procedure, functionality of the nerve may possibly be compromised, affecting the nerve to no longer transmit the warning sign from and to the brain to the muscles and skin and decreasing or abolishing functionality.

The injuries to the nerve can be initiated by any direct shock, for example an impact due to the drop or else due to traction wounds from the accidents of motor vehicle or else sharp disruption, for example straight slashes from a knife. Harm to a nerve can halt warning sign to and from the brain. Operating nerve restoration comprises the investigation of the damaged nerve and the elimination of damaged soft tissue from the nerve terminations. Nerve Repair Biomaterial products are utilized over surgical interferences to re-establish usual function in nerves.

The global Nerve Repair Biomaterial Market is witnessing speedy development owing to greater frequency of neurological complaints & nerve injuries, growing elderly residents, augmented finance by the government, and advantageous strategies for compensation. The demand for nerve repair biomaterials is growing in the hospitals. Owing to the growing number of elderly people and increasing number of nerve surgeries & nerve injuries, the demand for nerve repair biomaterials is also growing in the ambulatory trauma centers. These centers are tracking the hospitals.

Download PDFto know more details about "Nerve Repair Biomaterial Market" report 2028.

Drivers

Growth in the aged populace, greater frequency of nerve injuries, and increasing occurrence of infants having nervous complaints is estimated to perform such as a motivator for the development of the Nerve Repair Biomaterial Market.

Restraints

Absence of consciousness in the emerging areas is likely to restrain the development of the Nerve Repair Biomaterial Market.

Classification

The global Nerve Repair Biomaterial Market can be classified by End Users, Type of Injury, Nerve Protection, and Type of Product. By End Users, it can be classified as Ambulatory Trauma Centers, Hospital, and Clinics. By Type of Injury, it can be classified as Group Fascicular Repair, Epineural Nerve Repair, Perineural Nerve Repair. By Nerve Protection, it can be classified as Nerve Wrap, Nerve Protectors. By Type of Product, it can be classified as Nerve Graft, Nerve Repair.

Regional Lookout

By Region the global Nerve Repair Biomaterial Market can be classified as North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa.

Companies

Some of the important companies for Nerve Repair Biomaterial Market are Neurotex, Polyganics, Axo Gen Inc., Collagen Matrix, Synovis Micro Companies Alliance, Inc., Checkpoint Surgical, Inc., Stryker Corporation, and Collagen Matrix, Inc.

Access 109 page research report with TOC on "Nerve Repair Biomaterial Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/2013-2028-report-on-global-nerve-repair-biomaterial-market

This report provides detailed historical analysis of global market for Nerve Repair Biomaterial from 2013-2018, and provides extensive market forecasts from 2019-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Nerve Repair Biomaterial market.

Browse reports of similar category available with Radiant Insights, Inc.:

About Radiant Insights, Inc.:

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact:Michelle Thoras.Corporate Sales SpecialistRadiant Insights, Inc.Phone: +1-415-349-0054Toll Free: 1-888-928-9744Email: [emailprotected] Web: https://www.radiantinsights.com/Blog: https://radiantinsightsinc.blogspot.com/

SOURCE Radiant Insights, Inc.

Read the rest here:
Nerve Repair Biomaterial Market to Witness Speedy Development Owing to Greater Frequency of Neurological Complaints and Nerve Injuries by 2028:...

Loss of Smell, Confusion, Strokes: Does COVID-19 Target the Nervous System? – Discover Magazine

For many people, a sudden loss of smell is the first sign that somethings wrong. One gentleman said he realized it with hand sanitizer, says Carol Yan, a rhinologist at the University of California, San Diego. All of a sudden it was like water to him. The loss of smell, or anosmia, is such a common symptom of Covid-19 that the US Centers for Disease Control and Prevention recently added it to its official list.

The loss of smell (or taste) is one of many emerging hints that the SARS-CoV-2 virus may affect the nervous system. Physicians around the world have documented neurological symptoms in a significant fraction of Covid-19 patients. Some patients have experienced headaches, dizziness and other relatively minor symptoms, while others have had more serious problems like confusion and impaired movement, and even seizures and strokes.

Such reports have been circulating on message boards used by physicians, and they are just now making their way into the peer-reviewed scientific literature. Nobody knows at this point how widespread neurological symptoms are, nor the extent to which they contribute to the overall clinical picture for Covid-19.

Another huge unknown is whether SARS-CoV-2 can attack the nervous system directly by infecting neurons as rabies and a number of other viruses do or cause neurological symptoms indirectly, by triggering rampant inflammation or blood clotting.

These are critical questions, says Samuel Pleasure, a neuroscientist and neurologist at the University of California, San Francisco. For a small number of patients, neurological symptoms seem to be the earliest or even the only indicator of infection. For others, lingering or post-infection neurological problems could complicate recovery. We dont know whether or not thats going to be the case yet, but its an important unanswered question, says Pleasure.

Reports of lost taste and smell often in the absence of the kind of nasal congestion that interferes with olfaction with the common cold have been circulating for months. In one of the first peer-reviewed journal articles on the subject, Yan and colleagues describe results from an online survey of 262 patients in the UCSD hospital system. Slightly more than two-thirds of those who tested positive for Covid-19 experienced taste and smell deficits.

The deficits werent subtle, Yan says. Most people went from like a ten to zero. Fortunately, as patients get better, they seem to be regaining their sensory abilities, usually within a few weeks, the team reported April 12 in the International Forum of Allergy & Rhinology.

In an April 22 letter to the Journal of the American Medical Association, physicians reported a similar prevalence of anosmia in Covid-19positive patients at a regional hospital in Treviso, Italy. For 12 percent of these patients, the loss of smell occurred prior to other symptoms. For 3 percent, it was the only symptom they ever experienced.

Such reports have prompted several medical associations for ear, nose and throat specialists to issue statements urging physicians to consider anosmia as a potential screening tool for Covid-19 and to advise patients who experience a sudden loss of smell to consider self-isolating.

In theory, SARS-CoV-2 could get into the brain through several routes. The virus could enter the brain through the bloodstream if it can get past the cellular defense wall known as the blood-brain barrier. Or it could conceivably infect olfactory neurons in the nasal cavity or peripheral nerves elsewhere in the body and hitchhike into the brain along their axons. Scientists don't yet know which, if any, of these routes the virus can take.

Yan speculates that the presence of anosmia could turn out to be a a clue to how the disease might progress. She notes that most patients in her study had relatively mild cases of Covid-19 most were not hospitalized, and none required a ventilator to help them breathe. In contrast, other researchers have found a lower prevalence of anosmia among sicker patients. One possibility, Yan says, is that anosmia is more common in mild cases because the virus mostly stays in the nasal cavity. In more severe cases, it infiltrates the lungs, causing more dangerous respiratory symptoms but fewer sensory deficits. At this point its just a hypothesis, but its one she and her colleagues plan to investigate.

Preliminary evidence suggests that SARS-CoV-2 does not directly infect olfactory neurons, the odor-detecting cells at the top of the nasal cavity, at least by its usual route. In April, two RNA sequencing studies one led by researchers at Harvard, another by a group in Switzerland concluded that olfactory neurons do not make two key proteins, including the ACE2 receptor, used by the virus to break into cells. (The findings were posted before publication on the website bioRxiv and have not yet been peer-reviewed.)

However, neighboring support cells do appear to produce these proteins. The sudden loss of smell in Covid-19 patients could result from the virus infecting these support cells and then either causing local inflammation or disrupting the cells role in maintaining the balance of ions that olfactory neurons need to function properly, says neuroscientist Sandeep Robert Datta, who led the Harvard study.

Reports of other neurological symptoms in Covid-19 patients have emerged from China, France and elsewhere. In one of the first studies, doctors in Wuhan, China, reported April 10 in JAMA Neurology that of 214 patients hospitalized there between mid-January and mid-February, slightly more than a third experienced neurological symptoms that ranged from dizziness and headache to (less commonly) impaired consciousness, movement difficulties and seizures.

In an April 15 letter to the New England Journal of Medicine, doctors in Strasbourg, France, reported an even higher prevalence of neurological symptoms in a group of patients there: 84 percent experienced symptoms that included prominent agitation and confusion and alterations to reflexes and muscle contractions that suggested neurological problems in the brain.

The role SARS-CoV-2 plays in such symptoms remains an open question, especially for sicker patients who are likely to have low oxygen levels or preexisting conditions that could cause the same symptoms, says Pleasure, who cowrote an editorial on the Chinese study. The kinds of symptoms that were more common in the more severe patients could be happening in part because the patients are so sick, not because they have Covid-19, he says.

There were scattered reports of neurological problems with SARS and MERS, respiratory syndromes caused by coronaviruses related to the one causing the current pandemic, but the prevalence of such symptoms wasnt well documented. There seem to be more such reports with Covid-19, but that could be because so many more people have been affected in total, not necessarily that those symptoms occur in a higher proportion of patients, says Stanley Perlman, an infectious disease researcher at the University of Iowa Carver College of Medicine. More than four million people (and counting) have been infected in the current pandemic, compared with about 8,000 for SARS and 2,500 for MERS.

Some researchers have speculated that SARS-CoV-2 may invade the nervous system and suppress respiratory centers in the brain, contributing to the severity of breathing problems. So far theres no direct evidence for that, but scientists say its not out of the question.

Pierre Talbot, a virologist at the Armand-Frappier Sant Biotechnologie Research Centre near Montreal, has long argued that coronaviruses could be an underestimated threat to the nervous system. In experiments with mice and cultured human neurons, his group has found evidence that a human coronavirus called OC43, a frequent cause of the common cold, can travel from the respiratory tract to the nervous system. In 2016, the researchers reported finding the virus in brain tissue from an 11-month-old boy who died of encephalitis, or inflammation of the brain. Coronaviruses can do much more than cause respiratory diseases, Talbot says. The neurological aspects of Covid-19 are not surprising.

In experiments with genetically engineered mice, Perlman and his colleagues previously found that SARS and MERS can infect olfactory neurons and travel along their axons to the brains olfactory bulb. From there, the viruses spread quickly throughout the brain. His lab plans to repeat those experiments with SARS-CoV-2, but he cautions that mouse experiments may not replicate what a virus does in people in real-world conditions. And the new virus may act differently as suggested by the bioRxiv studies that showed that the virus likely cant infect the human olfactory neurons using its usual tactics.

Many viruses, Perlman says, have evolved other ways of getting into the nervous system including tricks for slipping past the guardian cells of the blood-brain barrier, which normally keep blood-borne pathogens out of the brain. Its still far too early to know all that SARS-CoV-2 is capable of. This virus is teaching us so much, Perlman says. I wouldnt draw any conclusions. Experiments that might help resolve the issue, such as tests on spinal fluid or autopsied brain tissue from Covid-19 patients, have been delayed by safety concerns.

Loss of smell has been reported in many Covid-19 patients. Inhaled air comes into contact with olfactory neurons at the top of the nasal cavity, raising the possibility that SARS-CoV-2 could infect the neurons and travel into the olfactory bulb, a part of the brain. But preliminary work suggests the virus may not be able to infect olfactory neurons. Instead, it may infect the adjacent supporting and stem cells in the olfactory epithelium.

Even if SARS-CoV-2 does not directly attack the nervous system, it could cause neurological problems indirectly. One way it could do this is through rampant inflammation known as a cytokine storm. In a case study published in Radiology, doctors in Detroit reported brain scan abnormalities indicative of a rare encephalopathy linked to cytokine storms in an airline worker in her mid-50s who tested positive for the virus. Another concern is reports of mysterious abnormalities in blood clotting in young and middle-aged Covid-19 patients that may increase the risk of stroke.

Some secondary effects could take time to develop. In an April 17 letter to the New England Journal of Medicine, Italian doctors described five Covid-19 patients who developed GuillainBarr syndrome, a condition that starts with weakness and tingling in the extremities and can progress to more serious movement difficulties. GuillainBarr syndrome occurs after infection, such as with Campylobacter bacteria, a frequent cause of food poisoning, when antibodies made by the immune system to fight the bacteria end up attacking the nervous system instead.

If the same thing happens with SARS-CoV-2, Pleasure says, doctors may see a wave of post-infection neurological conditions like GuillainBarr in the months ahead. As with nearly everything related to Covid-19, the full impact wont be known for some time.

This article originally appeared inKnowable Magazine, an independent journalistic endeavor fromAnnual Reviews. Read the original storyhere.

Original post:
Loss of Smell, Confusion, Strokes: Does COVID-19 Target the Nervous System? - Discover Magazine

Value of Neurologic Disorders Therapeutics Market Predicted to Surpass US$ by the of 2035 2018 2028 Dagoretti News – Dagoretti News

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Neurologic Disorders Therapeutics Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Neurologic Disorders Therapeutics market. We have also provided absolute dollar opportunity and other types of market analysis on the global Neurologic Disorders Therapeutics market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Neurologic Disorders Therapeutics market. All findings and data on the global Neurologic Disorders Therapeutics market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Neurologic Disorders Therapeutics market available in different regions and countries.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6000&source=atm

The authors of the report have segmented the global Neurologic Disorders Therapeutics market as per product, application, and region. Segments of the global Neurologic Disorders Therapeutics market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Neurologic Disorders Therapeutics market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

Drivers and Restraints

There are several factors that are influencing the growth of the global neurologic disorders therapeutics market. One of the key driving factors is the increasing advances in the diagnosis of the different neurodegenerative indications. This has helped in increasing the demand for new therapeutics to effectively treat such neurodegenerative disorders. The early determination such disorders is difficult due to its complex nature of such disorders, lack of efficient diagnostics, and its fast progression. This has naturally helped in driving the activities of research and development for more effective treatment. Governments across the globe are also helping research institutes by allotting more funds for the development of new neurologic disorder therapeutics.

Global Neurologic Disorders Therapeutics Market: Geographical Outlook

The global neurologic disorders therapeutics market is primarily divided into five key regions viz. North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. Of these, the global neurologic disorders therapeutics market is primarily dominated by North America region. This is because of the high aging population in the region, advancements in technology, and highly developed healthcare infrastructure.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6000&source=atm

Neurologic Disorders Therapeutics Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Neurologic Disorders Therapeutics Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Neurologic Disorders Therapeutics Market in South, America region is also expected to grow in near future.

The Neurologic Disorders Therapeutics Market report highlights is as follows:

This Neurologic Disorders Therapeutics market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Neurologic Disorders Therapeutics Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Neurologic Disorders Therapeutics Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Neurologic Disorders Therapeutics Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=6000&source=atm

See original here:
Value of Neurologic Disorders Therapeutics Market Predicted to Surpass US$ by the of 2035 2018 2028 Dagoretti News - Dagoretti News